New Drug for Eczema

Apremilast May Benefit Patients With Moderate Or Severe Atopic Dermatitis.

MedPage Today (5/8, Bankhead) reported that, according to research presented at an investigative dermatology meeting, "half of patients with moderate or severe atopic dermatitis had at least 50% improvement in disease status when treated with an oral phosphodiesterase inhibitor" called apremilast. In fact, "overall, the mean Eczema Activity and Severity Index (EASI) score declined from 24.8 at baseline to 16.2 at the end of the study (P=0.002)" that involved 16 patients. What's more, "pruritus and disease-related quality of life also improved significantly."

http://www.bobbybukamd.com/ http://www.drbobby.com/ http://www.wbderm.com/ http://www.williamsburgderm.com/